What is the appropriate dosing and monitoring of mirtazapine (Remeron) for appetite stimulation?

Mirtazapine (Remeron) for Appetite Stimulation

Mirtazapine is not currently recommended as a standard appetite stimulant based on major oncology guidelines, despite emerging evidence showing it can increase energy intake in cancer patients with anorexia. 1

Guideline-Based Recommendations

Standard Appetite Stimulants in Cancer Cachexia

The 2020 ASCO guideline on cancer cachexia does not recommend mirtazapine as a standard treatment option. 1 The guideline explicitly states that despite considerable discussion about olanzapine (a similar agent), there is insufficient clinical trial data to recommend atypical antipsychotics for cancer cachexia at this time. 1

Established first-line options include: 1

• Megestrol acetate: 160 mg/day minimum effective dose (optimal dose), up to 480 mg/day maximum (Level of Evidence: B1) 1
• Medroxyprogesterone acetate (MPA): 200 mg/day minimum (Level of Evidence: B1) 1
• Corticosteroids: For patients with life expectancy of weeks to months (Level of Evidence: B1) 1

Dosing When Mirtazapine Is Used Off-Label

Standard Dosing from FDA Label

If mirtazapine is prescribed off-label for appetite stimulation, the FDA-approved dosing for depression should guide initial prescribing: 2

• Starting dose: 15 mg once daily, preferably in the evening before sleep 2
• Dose range: 15-45 mg/day 2
• Dose escalation: Do not increase more frequently than every 1-2 weeks due to the 20-40 hour elimination half-life 2

Lower Doses for Appetite/Nausea

Emerging evidence suggests lower doses may be effective for appetite stimulation with fewer side effects: 3, 4

• A 2024 RCT in NSCLC patients used 15 mg for 2 weeks, then escalated to 30 mg through week 8 3
• A 2012 case report demonstrated effectiveness at 7.5 mg daily for refractory nausea and appetite loss during chemotherapy, avoiding somnolence seen at higher doses 4

Evidence for Efficacy

Recent Clinical Trial Data

The highest quality recent evidence comes from a 2024 randomized, double-blind, placebo-controlled trial in 86 patients with advanced NSCLC and anorexia: 3

• Energy intake increased significantly at 4 weeks: +379.3 kcal (95% CI: 138.6-576.1; P < .001) 3
• Increased protein (+22.5 g), carbohydrates (+43.4 g), and fats (+13.2 g) at 4 weeks 3
• Fat intake remained significantly higher at 8 weeks (14.5 g vs 0.7 g; P = .02) 3
• Sarcopenia decreased from 82.8% to 57.1% (P = .03) at 8 weeks 3
• No difference in subjective appetite scores between groups 3

Key finding: Mirtazapine increased actual energy consumption without necessarily improving subjective appetite perception. 3

Monitoring and Safety

Adverse Effects to Monitor

Common side effects include: 2, 3, 5, 6

• Somnolence/sedation (most common) 2, 5, 6
• Increased appetite and weight gain (therapeutic in this context but monitor) 2, 5, 6
• Dizziness 6
• Nightmares: Reported at 2 weeks in the 2024 trial but resolved by weeks 4-8 3

Special Populations Requiring Dose Adjustment

Reduced clearance occurs in: 2

• Elderly patients: Use caution with dose selection; 75% renal excretion increases risk in age-related renal decline 2
• Moderate to severe renal impairment: Plasma levels may be increased 2
• Hepatic impairment: Plasma levels may be increased 2

Drug Interactions

Contraindications and warnings: 2

• Absolute contraindication: MAOIs (14-day washout required in either direction) 2
• Additive sedation: With diazepam and similar drugs 2

Discontinuation

Gradual taper is recommended rather than abrupt cessation to avoid withdrawal symptoms. 2 If intolerable symptoms occur during dose reduction, manage based on clinical response. 2

Mechanism of Action for Appetite

Mirtazapine blocks: 5

• Presynaptic alpha-2 adrenergic receptors 5
• Postsynaptic 5-HT2 and 5-HT3 receptors 5
• Histamine receptors (contributing to sedation and appetite stimulation) 5

This results in increased noradrenergic activity and specific serotonergic activity at 5-HT1A receptors, while blocking 5-HT3 receptors that mediate nausea. 5

Clinical Pitfalls

Common mistakes to avoid:

• Using mirtazapine as first-line: Guidelines support megestrol acetate or corticosteroids first in cancer cachexia 1
• Starting at 15 mg in sensitive patients: Consider 7.5 mg in elderly or those concerned about sedation 4
• Expecting immediate appetite improvement: The 2024 trial showed objective energy intake increased without subjective appetite score changes 3
• Ignoring nutritional counseling: Mirtazapine should complement, not replace, dietary assessment and advice 3